Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$3.21 USD

3.21
1,457,884

+0.25 (8.45%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $3.22 +0.01 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Voyager Therapeutics (VYGR) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.67% and -25.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer

by Zacks Equity Research

Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.

Zacks Equity Research

Implied Volatility Surging for Voyager (VYGR) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.

Kinjel Shah headshot

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

by Kinjel Shah

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -6.67% and -66.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 18.31% and 35.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Voyager Therapeutics (VYGR) Q1 Earnings Expected to Decline

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?

by Zacks Equity Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Voyager Therapeutics' (VYGR) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Voyager Therapeutics (VYGR).

Zacks Equity Research

Is the Options Market Predicting a Spike in Voyager (VYGR) Stock?

by Zacks Equity Research

Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.

Zacks Equity Research

Voyager (VYGR) in Focus: Stock Moves 5.7% Higher

by Zacks Equity Research

Voyager (VYGR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Voyager Therapeutics (VYGR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1294.74% and 171.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 69.33% and 77.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session

by Zacks Equity Research

Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Zacks Equity Research

Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?

by Zacks Equity Research

Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Earnings Preview: Voyager Therapeutics (VYGR) Q1 Earnings Expected to Decline

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 58.02% and 253.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Earnings Season Could Be Great for Voyager Therapeutics (VYGR)

by Zacks Equity Research

Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 50.60% and 419.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.